C
CRYOPORT INC
NASDAQ: CYRX (CryoPort, Inc.)
Last update: 10 hours ago5.56
0.02 (0.36%)
| Previous Close | 5.54 |
| Open | 5.61 |
| Volume | 19,439 |
| Avg. Volume (3M) | 499,156 |
| Market Cap | 277,501,824 |
| Price / Sales | 1.21 |
| Price / Book | 0.760 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 |
| Profit Margin | -50.25% |
| Operating Margin (TTM) | -27.44% |
| Diluted EPS (TTM) | -2.49 |
| Quarterly Revenue Growth (YOY) | 4.00% |
| Total Debt/Equity (MRQ) | 62.38% |
| Current Ratio (MRQ) | 5.29 |
| Operating Cash Flow (TTM) | -16.32 M |
| Levered Free Cash Flow (TTM) | -9.81 M |
| Return on Assets (TTM) | -4.98% |
| Return on Equity (TTM) | -25.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Integrated Freight & Logistics (US) | Bearish | Bearish |
| Integrated Freight & Logistics (Global) | Bearish | Bearish | |
| Stock | CryoPort, Inc. | Bullish | Bearish |
AIStockmoo Score
1.0
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas. |
|
| Sector | Industrials |
| Industry | Integrated Freight & Logistics |
| Investment Style | Small Value |
| % Held by Insiders | 2.65% |
| % Held by Institutions | 100.43% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Thematics Asset Management | 31 Dec 2024 | 1,705,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (Roth MKM, 169.78%) | Buy |
| Median | 11.00 (97.84%) | |
| Low | 7.00 (Morgan Stanley, 25.90%) | Hold |
| Average | 10.80 (94.25%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 5.73 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 08 May 2025 | 11.00 (97.84%) | Buy | 5.44 |
| 16 Apr 2025 | 11.00 (97.84%) | Buy | 5.61 | |
| Morgan Stanley | 05 May 2025 | 7.00 (25.90%) | Hold | 5.44 |
| Guggenheim | 16 Apr 2025 | 10.00 (79.86%) | Buy | 5.61 |
| Roth MKM | 01 Apr 2025 | 15.00 (169.78%) | Buy | 6.09 |
| UBS | 01 Apr 2025 | 11.00 (97.84%) | Buy | 6.09 |
| 24 Mar 2025 | 10.00 (79.86%) | Buy | 7.10 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Apr 2025 | Announcement | Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025 |
| 31 Mar 2025 | Announcement | DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics" |
| 31 Mar 2025 | Announcement | Cryoport to Host Investor Call to Discuss Recent Strategic Agreement and Transformative Transaction Today, March 31, 2025, at 8:30 a.m. ET |
| 12 Mar 2025 | Announcement | Cryoport's MVE Biological Solutions Expands High-Efficiency Cryogenic Freezer Series With Answer to Evolving Needs of Fertility Clinics, Biorepositories and Clinical Laboratories |
| 04 Mar 2025 | Announcement | Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results |
| 18 Feb 2025 | Announcement | Cryoport to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |